Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 12
Submit an article Journal homepage
3,254
Views
17
CrossRef citations to date
0
Altmetric
Bedside to Bench Report

Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer

Maria Tsolia Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaCorrespondence[email protected]
View further author information
,
Carol Wadhama Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Mark Pineseb Prince of Wales Clinical School, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Tim Failesc ACRF Drug Discovery Centre for Childhood Cancer, Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Swapna Joshia Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Emily Moulda Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Julia X. Yind Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, University of New South Wales, Randwick, New South Wales, Australia;e Cure Brain Cancer Neuro-Oncology Group, Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Velimir Gayevskiyf Bioinformatics and Cancer Genomics, Peter MacCallum Cancer Centre, The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, AustraliaView further author information
,
Amit Kumarf Bioinformatics and Cancer Genomics, Peter MacCallum Cancer Centre, The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia;g Bioinformatics Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria, AustraliaView further author information
,
Warren Kapland Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Paul G. Ekerta Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, Australia;h Cell Biology, Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Melbourne, Victoria, AustraliaView further author information
,
Federica Salettai Children’s Cancer Research Unit, The Children’s Hospital at Westmead, Westmead, NSW, AustraliaView further author information
,
Laura Franshawa Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Jie Liua Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Andrew Gifforda Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, Australia;j Anatomical Pathology, Prince of Wales Hospital, Randwick, New South Wales, AustraliaView further author information
,
Martin A. Weberj Anatomical Pathology, Prince of Wales Hospital, Randwick, New South Wales, AustraliaView further author information
,
Michael Rodriguezj Anatomical Pathology, Prince of Wales Hospital, Randwick, New South Wales, AustraliaView further author information
,
Richard J. Cohnk Kids Cancer Centre, Sydney Children’s Hospital, Randwick, New South Wales, AustraliaView further author information
,
Greg Arndtc ACRF Drug Discovery Centre for Childhood Cancer, Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Vanessa Tyrrella Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Michelle Habera Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Toby Trahaira Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, Australia;k Kids Cancer Centre, Sydney Children’s Hospital, Randwick, New South Wales, AustraliaORCID Iconhttps://orcid.org/0000-0002-3295-228XView further author information
ORCID Icon,
Glenn M. Marshalla Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, Australia;k Kids Cancer Centre, Sydney Children’s Hospital, Randwick, New South Wales, AustraliaView further author information
,
Kerrie McDonaldb Prince of Wales Clinical School, University of New South Wales, Randwick, New South Wales, Australia;e Cure Brain Cancer Neuro-Oncology Group, Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
,
Mark J. Cowleyd Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, University of New South Wales, Randwick, New South Wales, Australia;l St Vincent’s Clinical School, University of New South Wales, Randwick, New South Wales, AustraliaView further author information
&
David S. Zieglera Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick, New South Wales, Australia;k Kids Cancer Centre, Sydney Children’s Hospital, Randwick, New South Wales, AustraliaView further author information
 show all
Pages 1078-1087 | Received 12 Jan 2018, Accepted 17 Jun 2018, Published online: 09 Oct 2018

References

  • Worst BC, Van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, et al. Next-generation personalized medicine for high-risk pediatric cancer patients - The INFORM pilot study. Eur J Cancer. 2016;65:91–101. doi:10.1016/j.ejca.2016.06.009.
  • Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131:903–910. doi:10.1007/s00401-015-1519-8.
  • Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, Limon D, Yust-Katz S, Lokiec A, Ram Z, Ross JS, et al. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. J Neurooncol. 2016;130:211–219. doi:10.1007/s11060-016-2237-3.
  • Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017;23:1028–1035. doi:10.1038/nm.4389.
  • Jones C, Baker SJ. Unique genetic and epigenetic mechanisms driving pediatric diffuse high-grade glioma. Nat Rev Cancer. 2014;14:651–661. doi:10.1038/nrc3811.
  • Subashi E, Cordero FJ, Halvorson KG, Qi Y, Nouls JC, Becher OJ, Johnson GA. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. J Neurooncol. 2016;126:243–251. doi:10.1007/s11060-015-1969-9.
  • Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, et al. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell. 2016;29:508–522. doi:10.1016/j.ccell.2016.03.002.
  • Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(Suppl 4):iv1–63. doi:10.1093/neuonc/nou223.
  • Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol. 2011;13:317–323. doi:10.1093/neuonc/noq191.
  • Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–477. doi:10.1016/j.cell.2013.09.034.
  • Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014;14:258. doi:10.1186/1471-2407-14-258.
  • Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61:1101–1103. doi:10.1002/pbc.24891.
  • Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DTW, Sturm D, Hermann C, Segura Wang M, et al. Atypical |CAPES. Cancer Cell. 2016;29:379–393. doi:10.1016/j.ccell.2016.02.001.
  • Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin A, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi:10.1038/nature12477.
  • Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979–993. doi:10.1016/j.cell.2012.04.024.
  • Ishibashi Y, Miyoshi H, Hiraoka K, Arakawa F, Haraguchi T, Nakashima S, Hashiguchi T, Shoda T, Hamada T, Okawa T, et al. Anaplastic lymphoma kinase protein expression, genetic abnormalities, and phosphorylation in soft tissue tumors: phosphorylation is associated with recurrent metastasis. Oncol Rep. 2015;33:1667–1674. doi:10.3892/or.2015.3806.
  • Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, et al. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med. 2016;8:133. doi:10.1186/s13073-016-0389-6.
  • Mody RJ, Wu Y, Lonigro RJ, Cao X, Roychowdhury S, Pea V, Frank KM, Prensner JR, Asangani I, Palanisamy N, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314:913–925. doi:10.1001/jama.2015.10080.
  • Parsons D, Roy A, Yang Y, Wang T, Scollon S, Kea B, Kerstein RA, Gutierrez S, Petersen AK, Bavle A, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2:616–624. doi:10.1001/jamaoncol.2015.5699.
  • Harris M, DuBois S, Glade Bender JL, Kim A, Crompton BD, Eea P, Dumont IP, Hong AL, Guo D, Church A, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (icat) study. JAMA Oncol. 2016;2:608–615. doi:10.1001/jamaoncol.2015.5689.
  • Chang W, Brohl AS, Patidar R, Sindiri S, Shern JF, Wei J, Song YK, Yohe ME, Gryder B, Zhang S, et al. Multidimensional ClinOmics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: a report from the center for cancer research. Clin Cancer Res. 2016;22:3810–3820. doi:10.1158/1078-0432.CCR-15-2717.
  • Lukas RV, Boire A, Nicholas MK. Targeted therapy in the treatment of malignant gliomas. Oncotargets Ther. 2009;2:115–133.
  • Vignoli A, Lesma E, Alfano RM, Peron A, Scornavacca GF, Massimino M, Schiavello E, Ancona S, Cerati M, Bulfamante G, et al. Glioblastoma multiforme in a child with tuberous sclerosis complex. Am J Med Genet A. 2015;167A:2388–2393. doi:10.1002/ajmg.a.37158.
  • Brown JM. Tuberose sclerosis with malignant astrocytoma. Med J Aust. 1975;1:811–814.
  • Padmalatha C, Harruff RC, Ganick D, Hafez GB. Glioblastoma multiforme with tuberous sclerosis. Report of a case. Arch Pathol Lab Med. 1980;104:649–650.
  • Matsumura H, Takimoto H, Shimada N, Hirata M, Ohnishi T, Hayakawa T. Glioblastoma following radiotherapy in a patient with tuberous sclerosis. Neurol Med Chir (Tokyo). 1998;38:287–291.
  • Reyes D, Prayson R. Glioblastoma in the setting of tuberous sclerosis. J Clin Neurosci. 2015;22:907–908. doi:10.1016/j.jocn.2014.12.001.
  • Parry L, Maynard JH, Patel A, Hodges AK, Von Deimling A, Sampson JR, Cheadle JP. Molecular analysis of the TSC1 and TSC2 tumor suppressor genes in sporadic glial and glioneuronal tumors. Hum Genet. 2000;107:350–356.
  • Yamada D, Hoshii T, Tanaka S, Hegazy AM, Kobayashi M, Tadokoro Y, Ohta K, Ueno M, Ali MAE, Hirao A. Loss of Tsc1 accelerates malignant gliomagenesis when combined with oncogenic signals. J Biochem. 2014;155:227–233. doi:10.1093/jb/mvt112.
  • Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang D-AK, Tönjes M, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in pediatric glioblastoma. Nature. 2012;482:226–231. doi:10.1038/nature10833.
  • Adamski J, Tabori U, Bouffet E. Advances in the management of pediatric high-grade glioma. Curr Oncol Rep. 2014;16:414. doi:10.1007/s11912-014-0414-0.
  • Kim SH, Kowalski ML, Carson RP, Bridges LR, Ess KC. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish. Dis Model Mech. 2013;6:925–933. doi:10.1242/dmm.011494.
  • Habib SL, Yadav A, Mahimainathan L, Valente AJ. Regulation of PI 3-K, PTEN, p53, and mTOR in malignant and benign tumors deficient in tuberin. Genes Cancer. 2011;2:1051–1060. doi:10.1177/1947601912445376.
  • Guo Y, Chirieac LR, Bueno R, Pass H, Wu W, Malinowska IA, Kwiatkowski DJ. Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene. 2014;33:3151–3160. doi:10.1038/onc.2013.280.
  • Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, Fujikawa K, Bjornsson J, Bernstein J, Henske EP. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer. 1998;83:2208–2216.
  • Astrinidis A, Senapedis W, Henske EP. Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner. Hum Mol Genet. 2006;15:287–297. doi:10.1093/hmg/ddi444.
  • Valianou M, Cox AM, Pichette B, Hartley S, Paladhi UR, Astrinidis A. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. Cell Cycle. 2015;14:399–407. doi:10.4161/15384101.2014.986394.
  • McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med. 2014;4:a014266–a014266. doi:10.1101/cshperspect.a014266.
  • Posternak V, Cole MD. Strategically targeting MYC in cancer. F1000Res. 2016;5:408. doi:10.12688/f1000research.
  • Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016;8:116. doi:10.1186/s13073-016-0366-0.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.